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Abstract
Background: Good Clinical Practice guidelines issued in 2016 encourage risk-based approaches to monitoring
clinical trials. This study compared current risk assessment and monitoring approaches in UK Clinical Trials Units
(CTUs) with the published guidance and makes recommendations for risk-based monitoring in pragmatic trials.
Methods: An online survey of UK Clinical Research Collaboration registered CTUs was administered via email
invitation. Forty-nine units were invited, and 23 responded. Respondents were also invited to share copies of risk
assessment templates.
Results: Most CTUs reported using remote combined with on-site monitoring. All reported undertaking a risk
assessment for Clinical Trials of Investigational Medicinal Products (CTIMPs) and 21 units did so for non-CTIMPs.
Most CTIMP risk assessments used MHRA (Medicines and Healthcare products Regulatory Agency) classifications,
although some also employed staff judgement. Almost all units based their monitoring on perceived risk level; this
number was higher for CTIMPs (n = 22) than for non-CTIMPs (n = 19). In most cases, monitoring plans were
produced. More CTUs revisited risk assessments during trials in CTIMPs (n = 21) than in non-CTIMPs (n = 18). Small
numbers of units reviewed the monitoring approach always (n = 4) or sometimes (n = 9) and few used the
reflection to guide future monitoring.
Conclusions: A high proportion of UK CTUs are using risk-based monitoring in the UK, as recommended by
guidelines, for both CTIMPs and non-CTIMPs. This has the potential to make trials more efficient and reduce costs.
However, there appears to be a lack of reflection on the value of these revised approaches. There may be a benefit
in CTUs collaborating nationally to improve processes for reflection and making changes during the life course of a
trial.
Keywords: Risk-based monitoring, Risk assessment, Risk-adapted monitoring
Background
Monitoring of clinical trials forms one of the main ap-
proaches to ensuring that quality standards are delivered
in line with International Council for Harmonisation of
Technical Requirements for Pharmaceuticals for Human
Use Good Clinical Practice (ICH-GCP) guidelines [1].
Trial sponsors are expected to have monitoring arrange-
ments in place to ensure that regulatory obligations are
met, the safety and well-being of participants are main-
tained, and scientific integrity is retained [1]. The ICH-
GCP guidance does not specify methods to be used but
recommends “considerations such as the objective,
purpose, design, complexity, blinding, size and endpoints
of the trial” [1].
Historically, trial monitoring has been onerous, involv-
ing numerous on-site visits and up to 100% source data
verification (SDV) [2] and having large implications for
trial management and budgets. SDV is the process by
which the data collected for a trial are compared with the
original source of information. More recently, there has
been a shift toward increased remote monitoring con-
ducted by the trial sponsor or coordinating trials unit or
both [3]. Central checks can be carried out on electronic
records, consent forms and overall performance of partici-
pating sites [3], highlighted by the recent development of
metrics in this area [4]. Although this may reduce the
number or duration of visits, central monitoring has its
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own limitations, including access to the source data and
reliance on sites maintaining data collection records. A
2012 survey highlighted that of 48 UK Clinical Research
Collaboration (UKCRC) registered Clinical Trials Units
(CTUs), 35% indicated that all trials had a documented
monitoring plan, and most CTUs used some level of cen-
tral monitoring, in some cases combined with on-site
monitoring [5].
In 2016, the integrated addendum to ICH-GCP was
published, building on the guidance jointly published by
the Medicines and Healthcare products Regulatory
Agency (MHRA), the Department of Health, and the
Medical Research Council in 2011 [6], encouraging
sponsors to develop more systematic and risk-based ap-
proaches to monitoring [7]. This uses the initial risk as-
sessment completed early on in a trial to assess the level
of monitoring required. For example, if a trial is assessed
as high-risk, more frequent site visits may be required,
whereas low-risk trials may not require any on-site mon-
itoring [3]. Risk-based approaches may include focusing
SDV on specific critical data points [8]. ICH-GCP rec-
ommendations state that “statistically controlled sam-
pling may be an acceptable method for selecting the
data to be verified”, suggesting that 100% SDV is not al-
ways necessary [1]. Other risk-based approaches may in-
clude reducing activities required on-site, such as
obtaining participant consent to allow documents (e.g.,
consent forms) to be sent to the coordinating centre for
central review [8], and resolving data queries remotely
through interrogation of electronic systems. In 2012,
53% of CTUs surveyed used a risk assessment to deter-
mine the level of monitoring required [5].
Although guidelines now recommend a risk-based
monitoring approach, it is not known how widely this
process has been adopted across UK CTUs. A recent
study in Ireland, for example, identified that only 21% of
respondents had performed risk-based monitoring [9].
Furthermore, the very nature of a risk-adaptive approach
suggests that this should be revisited throughout a trial,
assessing whether the chosen monitoring approach re-
mains adequate following trial protocol changes and
whether new risks have been identified. There is cur-
rently limited evidence regarding reflections on chosen
monitoring approaches at the end of a trial. This would
provide insight into lessons learnt and inform decisions
about future trials.
We therefore developed a survey, administered to repre-
sentatives from UKCRC registered CTUs, to determine
current monitoring practices and how these approaches
are being reflected upon at the end of a trial. Responses
were considered in relation to existing literature and best
practice guidelines on risk-based monitoring to allow us
to make recommendations for undertaking, and reflecting
upon, risk-based monitoring in pragmatic trials.
Methods
The survey was developed by using Google Forms and
structured, where possible, using skip logic so that re-
spondents could avoid having to scroll through irrele-
vant questions. The content was developed taking into
account existing literature on the topic, particularly fo-
cusing on reflection and learning from approaches used,
and through discussion with colleagues in Sheffield
CTU.
Almost all of the questions used tick boxes to min-
imise the burden on respondents. The researchers
undertook extensive testing of the survey prior to its
launch, particularly in relation to the use of the skip
logic.
The survey had five sections: general information
about the trial portfolios and approaches to monitoring,
the initial risk assessment of trials, monitoring ap-
proaches and adapting to risks identified in trials, reflect-
ing on the monitoring approach taken and the use of
this information, and a “catch-all” for any further infor-
mation that participants wished to provide. The full sur-
vey is reproduced in Additional file 1.
Questions were asked separately for Clinical Trial of an
Investigational Medicinal Product (CTIMP) and non-
CTIMP studies. A CTIMP is a trial looking at the safety
or efficacy of a medicine or placebo, as defined by the
Medicines for Human Use (Clinical Trials) Regulations
(2004). Non-CTIMP studies do not involve investigational
medicinal products and do not fall within the scope of the
Medicines for Human Use (Clinical Trials) Regulations
(2004).
The survey was designed to be completed on a unit-
level basis (i.e., one response per unit), and CTU direc-
tors were identified as the ideal recipients; they were
provided with the option of identifying other staff if they
felt they were not the best person to complete the sur-
vey. Contact was made at an early stage with the
UKCRC Network to discuss dissemination of the survey
and it was agreed that it would be distributed via their
CTU director email list, which had the contact details of
all UK CTU directors (n = 49).
A link to the survey was contained within the email sent
out, which also had a participant information sheet at-
tached. As the survey was designed to be anonymous, con-
sent was considered to be implied by the completion of
the survey. Also for this reason, the survey could not be
designed to restrict multiple responses from the same unit
or person. Therefore, the documentation provided speci-
fied that there should be only one response per unit.
Follow-up reminder emails were sent out by the Net-
work at 2 and 4 weeks after the original invitation. These
contained the same information, along with a copy of
the survey. The design of the survey meant that ques-
tions were presented over a number of separate pages
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and so suggestions were received that it would be helpful
for potential respondents to see the whole survey.
Descriptive statistics, through the use of count data,
were used to present data on quantitative information
gathered from completed responses. Narrative summary
was used to present information from the answers to
qualitative questions and supplementary information
provided by respondents.
Results
Overview of current practices within Clinical Trials Units
for risk assessments and monitoring
The response rate of the survey was 47% (23/49 CTUs), and
all respondents indicated that their units coordinated both
CTIMP and non-CTIMPs; the vast majority (n = 18) coordi-
nated more than 10 non-CTIMPs and a significant number
of those (n = 6) coordinated more than 30. Numbers of
CTIMPs were smaller, and most units (n = 14) coordinated
fewer than 10. Further details are provided in Table 1.
More than half of the respondents reported that their risk
assessment processes did not differ between CTIMPs and
non-CTIMPs (n = 13), and the other 10 respondents stated
that there were differences between the types of project.
Of the 23 responses, 12 indicated that the CTU would
make the decision on the level of monitoring required, in
terms of the proportion of on-site versus remote monitoring.
Four said that the sponsor would make this decision, and five
suggested that both the sponsor and the CTU would decide
on the level of monitoring. A further two respondents se-
lected “other”: one stated that decisions were made by the
CTU with input from the chief investigator, and the other
stated that it would be the sponsor making the decision for
CTIMPs and the CTU deciding for non-CTIMPs.
There was a clear split in the approach to risk assessment
based on trial type; nearly half (n = 10) of the respondents
indicated that the risk assessment process differed depend-
ing on whether the trial was a CTIMP or not. The most
popular approach to monitoring for both CTIMP (n = 10)
and non-CTIMPs (n = 13) was the use of mainly remote
monitoring, with some on-site monitoring, although the
use of remote monitoring only was rare (n = 2) and oc-
curred only in the case of non-CTIMPs (Table 2).
Almost all undertook a risk assessment for at least
some of their trials regardless of whether they were
CTIMPs (n = 23) or not (n = 21). See Table 3 for further
information.
Assessment and categorisation of risk
Of the 23 CTUs responding, 19 stated that their risk as-
sessment for a CTIMP would use the MHRA categorisa-
tions (A/B/C) whereas the remaining four stated that
this would not be the case. The MHRA categorises study
risk by using the definitions below:
 Type A: no higher than the risk of standard medical
care
 Type B: somewhat higher than the risk of standard
medical care
 Type C: markedly higher than the risk of standard
medical care.
Tables 4 and 5 provide more information on how risks
are assessed.
Management of risk
For the question “Does the risk assessment tool indicate
specific monitoring approaches to be used to mitigate
the risks identified for a study?” (Table 6), there were 22
responses relating to CTIMPs and 19 responses for non-
CTIMPs. For CTIMPs, 13 indicated that the risk assess-
ment tool does indicate specific monitoring approaches
Table 1 How many current trials does your unit coordinate?
(n = 23)
Number of units coordinating each type of trial
CTIMPs Non-CTIMPs
Fewer than 5 7 3
Between 5 and 10 7 2
More than 10 9 18*
*Six units coordinate more than 30 trials. Abbreviation: CTIMP Clinical Trial of
an Investigational Medicinal Product
Table 2 What type of monitoring does your Clinical Trials Unit
use? (n = 23)
Number of units coordinating each type of trial
CTIMPs Non-CTIMPs
Only on-site monitoring 1 1
Mostly on-site monitoring with some
remote
5 2
On-site and remote monitoring in equal
proportion
7 5
Mostly remote monitoring with some on-site 10 13
Only remote monitoring 0 2
Abbreviations: CTIMP Clinical Trial of an Investigational Medicinal Product
Table 3 Do you undertake a risk assessment for your trials?
(n = 23)






Unknown frequency 0 1
No 0 2
Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
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to be used, but the picture was more uncertain for non-
CTIMPs and only nine respondents stated that this was
the case. In one response, for each type of trial, this infor-
mation was unknown. This was because this question was
not answered, although previous answers suggested that a
risk assessment was undertaken for both types of trial.
Despite this, almost all based their monitoring ap-
proach on the perceived level of risk for the trial for
both CTIMPs (n = 22/23) and non-CTIMPs (n = 19/21).
See Table 7 for further information.
Monitoring plans
For those respondents who indicated that their risk as-
sessment and monitoring processes differed between
CTIMPs and non-CTIMPs (n = 10), nine reported pro-
ducing a monitoring plan for all CTIMPs and the other
respondent reported that this was the case for most
CTIMPs. Only five respondents reported producing a
monitoring plan for all non-CTIMPs; one reported
“most” and one reported “some”. Three respondents
noted that monitoring plans were not produced at all for
non-CTIMPs.
Where respondents reported that their risk assess-
ment and monitoring processes were the same for all
trials (n = 13), a monitoring plan was produced in
nine units for all trials and four units for most trials.
Response to changes in risk assessment
Twenty-one out of twenty-two respondents reported
that risk assessments were revisited throughout the
course of a CTIMP and 18 out of 23 for non-
CTIMPs (Table 8). In one case, it could not be
determined whether a risk assessment was revisited
during a non-CTIMP, as the respondent previously
reported that risk assessments were completed for
non-CTIMPs but did not provide an answer to this
question.
Almost all respondents stated that reassessments were
used to adapt the initially agreed monitoring approaches
for CTIMPs (n = 20). This was slightly fewer but still a
majority for non-CTIMPs (n = 16). One response for
non-CTIMPs could not be determined, as an earlier an-
swer suggested that monitoring plans were revisited for
non-CTIMPs but the answer provided to this question
contradicts that.
Reflections
Of the 23 respondents, four reported that the monitor-
ing approach is always reflected upon at the end of the
trial, nine reported that the approach is sometimes
reflected upon, and 10 reported that it is not reflected
upon at all (Table 9).
For those who reported documenting reflections at the
end of a trial, respondents reported documenting these
as follows. In one case, it was not recorded where this
information is documented.
 “Minutes of the Quality Management Group that
reviews and approves Risk Assessment and
Monitoring Plans”
 “Central files in the Quality Assurance department -
review of non-compliances/issues/additional monitoring
required”
 “We have a lessons learnt database where
we encourage both positive and negative
lessons to be documented and the review
team would suggest potential actions to
either disseminate or act upon to improve
for ongoing/future studies”.
Table 4 Does the risk assessment assess and categorise each
individual risk or the risk of the trial as a whole? (n = 23 for
CTIMPs, n = 19 for non-CTIMPs)
Number of units coordinating each type of trial
CTIMPs Non-CTIMPs
Individual risks 15 12
Whole study 4 3
Both 4 4
Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
Table 5 How is a risk assessment undertaken? (n = 23 for
CTIMPs, n = 20 for non-CTIMPs)
Number of units coordinating each type of trial
CTIMPs Non-CTIMPs
Using numerical scores 3 2
Using staff judgement 6 6
Using both 13 11
Unknown 1 1
Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
Table 6 Does the risk assessment tool indicate specific
monitoring approaches to be used to mitigate the risks




Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
Table 7 Is the type of monitoring used dependent on the level




Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
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The use of reflections to inform future trials is detailed
in Table 10. For those who reported that this information
is used to guide monitoring approaches for future trials,
additional information was provided as follows:
 “It may influence how we cost for increased (or
decreased) frequency, intensity, triggers or type of
monitoring”.
 “Helped us understand what is manageable and
effective”.
 “Previous learning is always taken into account”.
 “Our monitoring strategy is generally based
around resource and key areas such as
informed consent and eligibility. Information
from previous trials will be used to improve
methods and outcomes of monitoring
although the overall strategy largely
remains unchanged”.
 “Informal intelligence will guide future monitoring
in similar studies. Individual trial teams are also
likely to take forward lessons learned to their next
trials”.
 “If actions are required to be performed to improve
processes, this is fed into the QMS [Quality
Management System]”.
 “Lessons learned from each study guide planning for
the next”.
 “Shared learning between staff. Staff involved in
original project invited to discuss monitoring
approach for next study”.
Respondents then were asked how they attempted to
ensure consistency in the assessment of risk across their
trials. Eighteen responded to this question and some
provided multiple answers.
 Standard templates are used for all risk assessments
(n = 7).
 Quality Assurance Manager/team has involvement
in/oversight of completed risk assessments
(n = 5).
 Same core staff/review committee review or have
input into risk assessments or both (n = 4)
 Sponsor process (n = 2)
 Input of senior staff with guidance in standard
operating procedures (n = 1)
 Completed by allocated research-and-development
staff member (n = 1)
 Input of senior staff (n = 1).
Discussion
Nearly half of the registered UK CTUs responded to this
survey, many with significant trial portfolios, thereby
providing a good overview of the current approach to
risk-based monitoring in the UK. Much of the informa-
tion received was not surprising; more non-CTIMPs
were undertaken than CTIMPs, and the approach to
monitoring and risk assessments in CTIMPs indicated
an understandably greater level of scrutiny and caution
than in non-CTIMPs.
It is interesting to note that when compared with the re-
sults of the work of Tudur Smith in 2012 [5], a significantly
larger percentage of trials units currently have a monitoring
plan for all trials (61%, n = 14/23; compared with 35%).
Furthermore, whilst the percentage of trials across units
using risk assessment to guide the monitoring approach
has remained largely unchanged (53% to 51%, n = 21/41 re-
sponses; Table 6), almost all use a risk-adaptive approach
to monitoring (93%, n = 41/44 responses; Table 7).
The use of a risk-adaptive approach is clearly import-
ant in terms of ensuring that monitoring is cost-effective
and appropriate to the needs of the trial. It is encour-
aging to see that almost all units are revisiting their risk
assessments during their trials, albeit most often in a re-
active manner to a specific issue or event, and that
Table 8 How often is the risk assessment revisited? (Participants
may have provided multiple answers; n = 21 Clinical Trials Units)
CTIMPs Non-CTIMPs
At a fixed time point (e.g., yearly) 9 5
Routinely after each protocol amendment 10 10
In reaction to a specific issue/event 12 13
Not applicable 2 4
Abbreviation: CTIMP Clinical Trial of an Investigational Medicinal Product
Table 9 Are reflections on monitoring approaches used,




Is the monitoring approach




Table 10 Are reflections used to guide monitoring approaches
in future trials?
Is the information used to
guide monitoring approaches
for future trials?
Yes No Not applicable
Is the monitoring approach
reflected upon at the end
of the trial?
Yes 2 2 0
Sometimes 7 0 2
No 2 0 8
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almost all are also using the information gathered to
adapt initially agreed monitoring approaches.
However, it is unclear from this survey how significant
such changes are in terms of the approach taken to
monitoring. Whilst the survey does indicate that moni-
toring is almost entirely based on the assessed risk level
of the trial, there is understandably going to be a signifi-
cant use of staff judgement in making such an assess-
ment. Such judgement, without clear mechanisms for
sharing information amongst colleagues about how deci-
sions are made, creates the potential for inconsistency in
monitoring approaches within units.
The risk assessment templates and associated docu-
mentation provided by some of the respondents (n = 4)
appeared to be thorough in their design, capturing a var-
iety of information, such as mitigating factors, processes
to be followed (including for risk assessment review),
and both pre- and post-award factors. However, of these
examples provided, only one of the four units indicated
that they always reflect on their monitoring approach at
the end of the trial, meaning that a lot of valuable infor-
mation is captured and then not used.
In terms of reflections on monitoring approaches more
widely, this was much more mixed across the units, and
almost half did not reflect at the end of a trial at all.
Even where reflection did take place, this was often not
documented. This raises questions as to how consistency
is maintained as well as how and whether learning takes
place. In cases where units did reflect on their approach
to monitoring, the responses provided indicated that this
provides valuable learning, particularly in terms of mak-
ing improvements for future trials (in terms of trial cost-
ing and eligibility and consent, for example).
Strengths and limitations
Working with the UKCRC Network on recruitment to
this study facilitated access to CTUs via a contact with
whom they were already familiar and ensured that all reg-
istered trials units were given the opportunity to partici-
pate. The recruitment figures were consistent with the
previous survey work carried out in this area [5]. A par-
ticular strength of this study has been the ability to draw
comparisons with previous work in this area through the
use of similar questions. Whilst only around half of regis-
tered trials units participated in the survey, this study was
able to gather valuable information in an area of limited
prior research. The study was also reported in accordance
with guidelines for survey research [10] Additional file 2.
The limited response to the survey is an obvious limi-
tation of this work (though a common feature in re-
search more generally), which makes it difficult to assess
how generalisable our results are in relation to the state
of monitoring across the UK more widely. In addition,
whilst monitoring reflections were a particular element
on which this study sought information, the focus of
questions was only on post-trial reflections; it would
have been useful to know what, if any, reflection takes
place during the course of a trial too.
Furthermore, there were issues of consistency in some
responses; one respondent provided an answer that was
contradicted by a later answer, and another unit com-
pleted the survey twice, providing slightly different re-
sponses. Attempts were made to clarify these issues but
this was possible in only one such case, as providing
contact details was optional. It is not known why one
unit completed the survey twice; where responses dif-
fered, these were excluded from the results.
There was also an issue related to viewing the survey
form as indicated by one potential respondent asking for
a copy of the survey prior to commencing completion.
This allowed the respondent to review the questions be-
fore answering, seeking input from colleagues where re-
quired, prior to submitting their response. Although a
PDF copy of the survey questions was included with the
reminder email, partial responses could not be saved
using the survey tool. This may have made it more diffi-
cult for respondents completing the survey prior to the
reminder being sent.
The design of the survey, which was largely option-
based and had limited amounts of free text, also meant
that assumptions sometimes had to be made from the
information provided. This was perhaps not ideal but
this was a conscious decision by the research team to
ensure that the survey was not burdensome to complete
and that we received as many responses as possible.
Where assumptions were made, these were a consensus
between the research team and were fully documented.
An assumption was also made around interpretation
of the word “pragmatic”; the authors considered this to
refer to trials which have real-world application, not ne-
cessarily just late-phase randomised controlled trials.
Therefore, it was expected that the study would cover
the vast majority of trials conducted within the UKCRC
CTU Network, but admittedly respondents may have
interpreted the term differently. Specifically, the defin-
ition of “pragmatic” is perhaps most widely considered
to apply to late-phase (phase III and IV) trials [11].
Finally, a potential limitation could be non-response
bias. We do not know whether the CTUs that did respond
are representative of all UKCRC CTUs. Whilst the target
population are all UKCRC-registered, implying a certain
level of consistency, the figures in Table 1 suggest that
those who did respond have relatively large trial portfolios.
This could mean that monitoring practices are more
established in a larger unit than perhaps smaller or more
recently registered units. Further work could try to deter-
mine how representative a sample our respondents were
in comparison with the UKCRC CTUs as a whole.
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Implications for practice
This research demonstrates that whilst the use of moni-
toring continues to grow, there is some variation in how
such monitoring is delivered. It is suggested that the
findings from this research should be used as a starting
point for discussion at the UKCRC Network level, per-
haps around the need for greater collaboration and re-
source-sharing on this topic.
Future research
As indicated previously, there are obvious limitations to
this research in providing only a “snapshot” of the current
approach to risk-based monitoring in UK. What our re-
search has found suggests that there would be value in a
more detailed, qualitative exploration of the topic.
Greater standardisation of processes, including reflect-
ing on monitoring approaches and recording this infor-
mation, is likely to have benefits beyond the units
themselves in terms of providing greater confidence to
research sponsors and investigators around the processes
that trials units have in place in this area.
Conclusions
This study provides a useful update on the use of risk-
based monitoring, indicating the increased use of a risk-
adaptive approach in the UK. Responses demonstrated
that most units have established approaches in place
around monitoring, including the use of risk assessments.
Despite this, our survey indicates that there is little re-
flection on the monitoring approach taken at the end of
the trial, documented or otherwise. Those units that did
undertake such reflection were able to demonstrate
through their responses the value that this provides in
developing staff knowledge and improving processes for
the benefit of future trials.
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